Samtidig administration af tenofovirdisoproxilfumarat og didanosin medførte en stigning på 40- 60% i systemisk eksponering over for didanosin, som kan øge risikoen for didanosin- relaterede bivirkninger.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse events.